September 30, 2014 / 12:06 AM / 4 years ago

Valeant Pharmaceuticals' third-quarter sales to rise

The head offices of Valeant Pharmaceuticals International Inc. are seen in Laval, Quebec May 20, 2014. REUTERS/Christinne Muschi

(Reuters) - Valeant Pharmaceuticals International Inc’s VRX.TO sales are expected to rise 15 percent in the third quarter but will face a tougher fourth-quarter comparison to year-ago results, Allergan Inc (AGN.N) said in a filing on Monday.

Allergan, the maker of Botox anti-wrinkle injections, has criticized Valeant’s acquisition-based business model as it attempts to fend off the drugmaker’s $51 billion hostile bid.

Valeant’s third-quarter sales will reflect a weak year-ago period for contact lens maker Bausch & Lomb, which Valeant acquired for $8.7 billion in August 2013, according to the filing.

The Canadian company did not give a specific fourth-quarter forecast but said last week that it expects continued strong double-digit same store organic growth in the fourth quarter. Valeant announced that it will report third-quarter earnings on Oct. 20.

Reporting by Susan Kelly in Chicago; Editing by Lisa Shumaker

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below